Literature DB >> 22657536

High initial default in patients with smear-positive pulmonary tuberculosis at a regional hospital in Accra, Ghana.

F K Afutu1, R Zachariah, S G Hinderaker, H Ntoah-Boadi, E Apori Obeng, F Adae Bonsu, A D Harries.   

Abstract

Sputum smear-positive TB patients, diagnosed in the laboratory, who never start anti-TB treatment are classified as 'initial defaulters'. In Ridge Hospital, Accra, Ghana, there were 84 laboratory confirmed TB cases in 2009, of whom 32 (38%) were initial defaulters. Cure and default rates based on this cohort were 54% and 43% respectively, compared with rates of 87% and 8% when using the cohort based on 52 patients registered for treatment. This study highlights the problem of initial defaulters, and shows that programme performance may be poor when patients in laboratory registers are used as the cohort to evaluate treatment outcomes.
Copyright © 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22657536     DOI: 10.1016/j.trstmh.2012.05.002

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  18 in total

1.  Pre-treatment loss to follow-up among smear-positive TB patients in tertiary hospitals, Quetta, Pakistan.

Authors:  A Wali; A M V Kumar; S G Hinderaker; E Heldal; E Qadeer; R Fatima; A Ullah; N Safdar; A Yaqoob; K Anwar; M Ul Haq
Journal:  Public Health Action       Date:  2017-03-21

2.  Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe.

Authors:  K Charambira; S Ade; A D Harries; R T Ncube; C Zishiri; C Sandy; H Mutunzi; K Takarinda; P Owiti; P Mafaune; P Chonzi
Journal:  Public Health Action       Date:  2016-06-21

3.  Alarming rates of attrition among tuberculosis patients in public-private facilities in Lahore, Pakistan.

Authors:  B J Khan; A M V Kumar; A Stewart; N M Khan; K Selvaraj; R Fatima; Z Samad
Journal:  Public Health Action       Date:  2017-06-21

Review 4.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis.

Authors:  Peter MacPherson; Rein M G J Houben; Judith R Glynn; Elizabeth L Corbett; Katharina Kranzer
Journal:  Bull World Health Organ       Date:  2013-11-22       Impact factor: 9.408

5.  Under-reporting of sputum smear-positive tuberculosis cases in Kenya.

Authors:  D Tollefson; F Ngari; M Mwakala; D Gethi; H Kipruto; K Cain; E Bloss
Journal:  Int J Tuberc Lung Dis       Date:  2016-10       Impact factor: 2.373

6.  Pre-treatment lost to follow-up tuberculosis patients, Chongwe, Zambia, 2017: a retrospective cohort study.

Authors:  M Chilembo; S Oguri; Y Matsuoka; M Ota; P Musiankuni; J Kabungo
Journal:  Public Health Action       Date:  2020-03-21

7.  The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Infect Dis       Date:  2017-12-07       Impact factor: 71.421

8.  Low tuberculosis case detection: a community and health facility based study of contributory factors in the Nkwanta South district of Ghana.

Authors:  Gregory K Amenuvegbe; Anto Francis; Binka Fred
Journal:  BMC Res Notes       Date:  2016-06-29

9.  Evaluation of gene xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study.

Authors:  Maxwell Oluwole Akanbi; Chad Achenbach; Babafemi Taiwo; John Idoko; Agatha Ani; Yetunde Isa; Oche Agbaji; Christiana Ukoli; Patrick Akande; Mamoudou Maiga; Robert Leo Murphy
Journal:  BMC Pulm Med       Date:  2017-05-30       Impact factor: 3.317

10.  Challenges from Tuberculosis Diagnosis to Care in Community-Based Active Case Finding among the Urban Poor in Cambodia: A Mixed-Methods Study.

Authors:  Natalie Lorent; Kimcheng Choun; Shelly Malhotra; Pichenda Koeut; Sopheak Thai; Kim Eam Khun; Robert Colebunders; Lut Lynen
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.